Oragenics Inc (OGEN)

$4.35 -0.01 (-0.23%)
Market Cap 3.12M
Revenue (ttm) 0.00
Net Income (ttm) -10.57M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 46,300
Avg Vol 256,133
Day's Range N/A - N/A
Shares Out 715,000.00
Stochastic %K 58%
Beta 0.94
Analysts Strong Buy
Price Target $2.00

Company Profile

Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002 for the treatment of mild traumatic brain injury, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplif...

Industry: Biotechnology
Sector: Healthcare
Phone: 813 286 7900
Fax: 813 286 7900
Address:
1990 Main Street, Suite 750, Sarasota, United States
NMax
NMax Jun. 16 at 11:09 PM
$OGEN Of the 266,667 shares Odyssey Health owns 10,000 were just "sold" or transferred.... **One week prior to when Oragenics is supposed to begin humans clinicals 2 and also present at Bio 2025**
0 · Reply
NMax
NMax Jun. 16 at 10:46 PM
$OGEN Odyssey may have washed a small fraction of their shares into another account. Adds to the docket. Long and strong 🤑🤑🤑
0 · Reply
RocketQueen
RocketQueen Jun. 16 at 7:57 PM
$OGEN still a piece of garbage that is going nowhere. 4.40/30 = .146 I’d get out before Janet starts bombing the float with the 350M share dilution. What this company is doing is criminal and they will pay a legal price for their actions.
0 · Reply
NMax
NMax Jun. 16 at 1:55 PM
$OGEN Unlike those shorting $OGEN I back up my sentiment with actual information. And I don't flip-flp my sentiment irrationally to manipulate others. With that said... A quick timeline of the last month or two: Racketqueen suddenly and in-explicably begins a fear-mongering campaign against holders, attacking holders credibility. During a panel this past May, Janet Huffman says human clinicals will begin this quarter and Oragenics has applied for a military grant. Oragenics reveals will be presenting presenting at the largest biotech conference, Bio 2025 1:30 Reverse split to consolidate shares Short pressure increasing horrible shares at zero borrowable fee skyrocketing to above 200% Racketqueen behavior tells us something about the state of mind of shorters and they seem very worried
1 · Reply
NMax
NMax Jun. 16 at 12:18 PM
$OGEN @Dh15708 Agreed💯%! People that have no faith or investments in this company moved on long ago. Racketqueens agenda to manipulate the few shareholders left into selling is completely transparent. Its sad. Continuing to accumulate! 🤑🤑🤑 Not a single doubt! 😁 Have a great week! 🙂
0 · Reply
Dh15708
Dh15708 Jun. 16 at 3:55 AM
$OGEN jeez ..some people just can't accept and move on but keep posting same boring nonsense over and over again You think that this company is fraud garbage than sell move on simple as that 🙃😉.
1 · Reply
RocketQueen
RocketQueen Jun. 15 at 8:44 PM
$OGEN this is a failed company that is still trying to run and old and tired scam. The board and officers need to be arrested and jailed for fraud.
0 · Reply
RocketQueen
RocketQueen Jun. 14 at 7:14 AM
$OGEN 4.36/30 = .145, there is no way this is going to recover. You’d be better off cutting your losses and moving on. Dilution around the corner. The board and officers belong in jail. I’m going to see if the SEC can shut them down before they steal more.
1 · Reply
NMax
NMax Jun. 13 at 11:03 PM
$OGEN The 144 filing is an intent to sell notification, which is needed for restricted shares. It does not mean they are dumping all their shares immediately, as that MGHA dingus tried to manipulate retail into believing. They have 90 days from the filing to sell shares at their discretion. IMPLICATION: they might be anticipating a catalyst or significant price boost OR they may decide to not do anything at all. They are under no obligation to sell. Its an interesting right before Bio2025
0 · Reply
NMax
NMax Jun. 13 at 8:35 PM
$OGEN @Mgha Companies with no facilities or personal don't stay listed this long unless they're part of an acquisition. Companies with no facilities/personal don't get partnerships with government institutions. They dont get partnerships with people like Leigh Steinberg, they don't have private placements, they don't get opportunities to present at Bio 2025 You're obvious trying to manipulate retail.
0 · Reply
Latest News on OGEN
Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia

May 13, 2025, 8:30 AM EDT - 4 weeks ago

Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia

Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision

May 12, 2025, 8:30 AM EDT - 5 weeks ago

Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision

Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit

Apr 7, 2025, 4:30 PM EDT - 2 months ago

Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit

Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress

Mar 27, 2025, 8:30 AM EDT - 2 months ago

Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress

Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K

Mar 18, 2025, 5:33 PM EDT - 3 months ago

Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K

Oragenics, Inc. Submits Investigator's Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)

Mar 6, 2025, 9:30 AM EST - 3 months ago

Oragenics, Inc. Submits Investigator's Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Present at the Emergencies in Medicine Conference on Advancing Concussion Treatment

Feb 25, 2025, 8:30 AM EST - 3 months ago

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Present at the Emergencies in Medicine Conference on Advancing Concussion Treatment

Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment

Feb 11, 2025, 8:30 AM EST - 4 months ago

Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025

Feb 5, 2025, 8:15 AM EST - 4 months ago

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025

Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO

Jan 21, 2025, 8:15 AM EST - 5 months ago

Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO

Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference

Dec 16, 2024, 8:09 AM EST - 6 months ago

Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference

Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit

Oct 18, 2024, 8:30 AM EDT - 8 months ago

Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit

Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation

Oct 9, 2024, 7:30 AM EDT - 8 months ago

Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation

Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002

Oct 8, 2024, 8:45 AM EDT - 8 months ago

Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002

Oragenics, Inc. Announces Closing of Public Offering

Sep 5, 2024, 4:30 PM EDT - 10 months ago

Oragenics, Inc. Announces Closing of Public Offering

Oragenics, Inc. Announces Pricing of Public Offering

Sep 4, 2024, 8:36 AM EDT - 10 months ago

Oragenics, Inc. Announces Pricing of Public Offering

Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients

Aug 21, 2024, 8:45 AM EDT - 10 months ago

Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients

Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards

Aug 16, 2024, 4:30 PM EDT - 10 months ago

Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards

Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range

Aug 14, 2024, 8:30 AM EDT - 10 months ago

Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range

Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study

Aug 12, 2024, 8:30 AM EDT - 11 months ago

Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study

Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing

Aug 8, 2024, 8:45 AM EDT - 11 months ago

Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing

Oragenics Develops Automated Intranasal Device for Treating Concussed Patients

Jun 27, 2024, 8:30 AM EDT - 1 year ago

Oragenics Develops Automated Intranasal Device for Treating Concussed Patients

Oragenics, Inc. Announces Proposed Public Offering

Jun 24, 2024, 6:43 PM EDT - 1 year ago

Oragenics, Inc. Announces Proposed Public Offering

Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer

May 22, 2024, 8:00 AM EDT - 1 year ago

Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer

Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine

May 17, 2024, 8:00 AM EDT - 1 year ago

Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine

Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

Apr 19, 2024, 5:50 PM EDT - 1 year ago

Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

Oragenics, Inc. Files 10K and Provides Company Update

Apr 1, 2024, 9:05 AM EDT - 1 year ago

Oragenics, Inc. Files 10K and Provides Company Update

Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

Mar 18, 2024, 7:00 AM EDT - 1 year ago

Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion

Mar 5, 2024, 7:45 AM EST - 1 year ago

Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion

Oragenics Announces Closing of Public Offering

Mar 1, 2024, 4:04 PM EST - 1 year ago

Oragenics Announces Closing of Public Offering

Oragenics Announces Pricing of Public Offering

Feb 27, 2024, 9:25 PM EST - 1 year ago

Oragenics Announces Pricing of Public Offering

Oragenics Announces Proposed Public Offering

Feb 27, 2024, 4:33 PM EST - 1 year ago

Oragenics Announces Proposed Public Offering

Oragenics, Inc. Announces Leadership Transition

Feb 12, 2024, 4:41 PM EST - 1 year ago

Oragenics, Inc. Announces Leadership Transition

Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement

Feb 7, 2024, 8:00 AM EST - 1 year ago

Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement

Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion

Feb 5, 2024, 8:00 AM EST - 1 year ago

Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion

Oragenics Announces Termination of At-The-Market Offering Program

Jan 23, 2024, 5:34 PM EST - 1 year ago

Oragenics Announces Termination of At-The-Market Offering Program

Oragenics Completes Acquisition of Odyssey Health's Neurological Assets

Jan 2, 2024, 7:30 AM EST - 1 year ago

Oragenics Completes Acquisition of Odyssey Health's Neurological Assets

Oragenics Issues Update to Shareholders

Nov 2, 2023, 7:00 AM EDT - 1 year ago

Oragenics Issues Update to Shareholders

Odyssey Health, Inc. Provides Update on Asset Purchase Agreement with Oragenics, Inc.

Oct 18, 2023, 8:30 AM EDT - 1 year ago

Odyssey Health, Inc. Provides Update on Asset Purchase Agreement with Oragenics, Inc.

Oragenics Announces Appointment of Bruce Cassidy and John Gandolfo to Board of Directors

Oct 18, 2023, 8:30 AM EDT - 1 year ago

Oragenics Announces Appointment of Bruce Cassidy and John Gandolfo to Board of Directors

Oragenics to Acquire Odyssey Health's Neurological Drug Technology Pipeline Including Concussion Drug Candidate

Oct 5, 2023, 6:30 AM EDT - 1 year ago

Oragenics to Acquire Odyssey Health's Neurological Drug Technology Pipeline Including Concussion Drug Candidate

Oragenics Enters into Agreement with Lantern Bioworks for Replacement-Therapy Assets

Sep 29, 2023, 4:00 PM EDT - 1 year ago

Oragenics Enters into Agreement with Lantern Bioworks for Replacement-Therapy Assets

Oragenics, Inc. Announces Private Placement

Aug 7, 2023, 8:30 AM EDT - 2 years ago

Oragenics, Inc. Announces Private Placement

Oragenics Project to Develop a Variant-Agnostic Protein Antigen for Use in its COVID-19 Intranasal Vaccine Receives Funding from CQDM

Jun 5, 2023, 4:18 PM EDT - 2 years ago

Oragenics Project to Develop a Variant-Agnostic Protein Antigen for Use in its COVID-19 Intranasal Vaccine Receives Funding from CQDM

Oragenics to Participate in the World Vaccine Congress Washington

Mar 29, 2023, 11:45 AM EDT - 2 years ago

Oragenics to Participate in the World Vaccine Congress Washington

Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE

Mar 14, 2023, 8:30 AM EDT - 2 years ago

Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE

Oragenics Appoints Janet Huffman as Chief Financial Officer Strengthening Executive Leadership Team

Mar 8, 2023, 9:09 AM EST - 2 years ago

Oragenics Appoints Janet Huffman as Chief Financial Officer Strengthening Executive Leadership Team

Oragenics Enters into an Exclusive Global License Agreement with Inspirevax to Develop Intranasal Covid Vaccine Candidate

Mar 1, 2023, 7:30 AM EST - 2 years ago

Oragenics Enters into an Exclusive Global License Agreement with Inspirevax to Develop Intranasal Covid Vaccine Candidate

Oragenics, Inc. Regains Compliance with NYSE American

Feb 3, 2023, 7:30 AM EST - 2 years ago

Oragenics, Inc. Regains Compliance with NYSE American

Oragenics, Inc. Discloses One-for-Sixty Reverse Stock Split

Dec 23, 2022, 4:05 PM EST - 2 years ago

Oragenics, Inc. Discloses One-for-Sixty Reverse Stock Split

NMax
NMax Jun. 16 at 11:09 PM
$OGEN Of the 266,667 shares Odyssey Health owns 10,000 were just "sold" or transferred.... **One week prior to when Oragenics is supposed to begin humans clinicals 2 and also present at Bio 2025**
0 · Reply
NMax
NMax Jun. 16 at 10:46 PM
$OGEN Odyssey may have washed a small fraction of their shares into another account. Adds to the docket. Long and strong 🤑🤑🤑
0 · Reply
RocketQueen
RocketQueen Jun. 16 at 7:57 PM
$OGEN still a piece of garbage that is going nowhere. 4.40/30 = .146 I’d get out before Janet starts bombing the float with the 350M share dilution. What this company is doing is criminal and they will pay a legal price for their actions.
0 · Reply
NMax
NMax Jun. 16 at 1:55 PM
$OGEN Unlike those shorting $OGEN I back up my sentiment with actual information. And I don't flip-flp my sentiment irrationally to manipulate others. With that said... A quick timeline of the last month or two: Racketqueen suddenly and in-explicably begins a fear-mongering campaign against holders, attacking holders credibility. During a panel this past May, Janet Huffman says human clinicals will begin this quarter and Oragenics has applied for a military grant. Oragenics reveals will be presenting presenting at the largest biotech conference, Bio 2025 1:30 Reverse split to consolidate shares Short pressure increasing horrible shares at zero borrowable fee skyrocketing to above 200% Racketqueen behavior tells us something about the state of mind of shorters and they seem very worried
1 · Reply
NMax
NMax Jun. 16 at 12:18 PM
$OGEN @Dh15708 Agreed💯%! People that have no faith or investments in this company moved on long ago. Racketqueens agenda to manipulate the few shareholders left into selling is completely transparent. Its sad. Continuing to accumulate! 🤑🤑🤑 Not a single doubt! 😁 Have a great week! 🙂
0 · Reply
Dh15708
Dh15708 Jun. 16 at 3:55 AM
$OGEN jeez ..some people just can't accept and move on but keep posting same boring nonsense over and over again You think that this company is fraud garbage than sell move on simple as that 🙃😉.
1 · Reply
RocketQueen
RocketQueen Jun. 15 at 8:44 PM
$OGEN this is a failed company that is still trying to run and old and tired scam. The board and officers need to be arrested and jailed for fraud.
0 · Reply
RocketQueen
RocketQueen Jun. 14 at 7:14 AM
$OGEN 4.36/30 = .145, there is no way this is going to recover. You’d be better off cutting your losses and moving on. Dilution around the corner. The board and officers belong in jail. I’m going to see if the SEC can shut them down before they steal more.
1 · Reply
NMax
NMax Jun. 13 at 11:03 PM
$OGEN The 144 filing is an intent to sell notification, which is needed for restricted shares. It does not mean they are dumping all their shares immediately, as that MGHA dingus tried to manipulate retail into believing. They have 90 days from the filing to sell shares at their discretion. IMPLICATION: they might be anticipating a catalyst or significant price boost OR they may decide to not do anything at all. They are under no obligation to sell. Its an interesting right before Bio2025
0 · Reply
NMax
NMax Jun. 13 at 8:35 PM
$OGEN @Mgha Companies with no facilities or personal don't stay listed this long unless they're part of an acquisition. Companies with no facilities/personal don't get partnerships with government institutions. They dont get partnerships with people like Leigh Steinberg, they don't have private placements, they don't get opportunities to present at Bio 2025 You're obvious trying to manipulate retail.
0 · Reply
hyerize
hyerize Jun. 13 at 8:29 PM
$OGEN either pay me already or take everything! Enough with all this bullshit! Missing out on so many other plays. 🙄🖕
0 · Reply
NMax
NMax Jun. 13 at 8:14 PM
$OGEN Ah yes, try to appear reasonable while attacking me. You've not addressed the questions I asked you. Why is that? I asked something reasonable regarding the situation. And your response is that I'm misleading people. That's a pretty crappy. These manipulator alts always fall back into the same pattern. Guess who's going to keep adding 🤑🤑🤑
0 · Reply
Mgha
Mgha Jun. 13 at 8:06 PM
$OGEN We are all in the same boat with Oragenics. If OGEN sinks, we all lose money—and that’s the last thing I want. I truly hope the company succeeds so at least some of us can recover our investments. For those of us who’ve been through two reverse splits, we know there’s no realistic way to fully recoup our losses unless OGEN reaches $100 or more—which is a tough ask. My main disagreement with MMax is that I believe he’s giving investors false hope, and that can be harmful.
0 · Reply
NMax
NMax Jun. 13 at 7:54 PM
$OGEN @Mgha Next, tell me why they'd sell right before an Oragenics business manager (that specializes in M&As) is about to present at the largest biotech conference?
0 · Reply
NMax
NMax Jun. 13 at 7:52 PM
$OGEN First off, Was that a sale or a proposed sale? Secondly, how hard do you think it'd be to wash those shares into a other account when the volume is this low and theirs so fee *ACTUAL* retail holders here?
0 · Reply
Mgha
Mgha Jun. 13 at 7:39 PM
$OGEN sec filing form 144 Insider sale of stock shares what kind of insider is selling right before acquisition? ? Can you explain to us Mmax please.
2 · Reply
Seaman23
Seaman23 Jun. 13 at 6:10 PM
$OGEN 🗑️🗑️🗑️
0 · Reply
Dh15708
Dh15708 Jun. 13 at 3:00 PM
$OGEN Upcoming week attending two conferences. Next two weeks they'll be PR. ADDDING.
1 · Reply
NMax
NMax Jun. 13 at 1:48 PM
$OGEN Continuing to accumulate! 🤑🤑🤑 Not a single doubt! 😁 Have a great weekend! 🙂
0 · Reply
RocketQueen
RocketQueen Jun. 12 at 8:46 PM
$OGEN 4.63/30 = .154, below the split point and compliance pre-spit. This is a failed company with a board and officers that just trying to milk as much as possible about out of a store front for a PONZI scam.
1 · Reply
NMax
NMax Jun. 12 at 6:58 PM
$OGEN getting a suspicion that there is an announcement related to this biotech conference...
1 · Reply
NMax
NMax Jun. 12 at 3:13 PM
$OGEN I will be adding. Period. I'm not trying to time a buyout 🤑🤑🤑 Long and strong. 💎🤲
0 · Reply